Navigation Links
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Date:5/15/2012

d a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; this mechanism induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical trial in Revlimid refractory and resistant deletion 5q MDS patients and a Phase 2b clinical trial in non-deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical-stage drug development company focused on discovering and developing small-molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome, followed by Telcyta®, a cancer-activated prodrug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small-molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating MDS, whether Telintra treatment results in hematologic improvement in patients with MDS, whether Telintra reduces the need for, or offer
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Regains Compliance With Minimum Bid Price Requirement
2. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
3. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
4. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
5. Telik Announces Third Quarter 2011 Financial Results
6. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
7. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
9. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
10. Telik Announces First Quarter 2011 Financial Results
11. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Japanese Study Suggests the Drug Improves Memory, SARASOTA, ... announced today that it has received positive,preliminary results ... a,promising new drug application for the treatment of ... in,September, is the first human clinical study conducted ...
... treated with maximally,tolerated lipid-lowering therapies experienced 50% ... other atherogenic,when treated with 300 mg/week ISIS ... 26, 2007,/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced,results ... of ISIS 301012 in,patients with homozygous familial ...
Cached Medicine Technology:Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... have a decreased risk of developing diabetes, according to ... The study found that// only 8 percent of the ... percent of those on older drugs. ,The ... Norvasc and Coversyl with a beta-blocker and a diuretic. ...
... The Journal of the American Medical Association finds that ... as ever. Doctors' training, or// residency includes shifts that ... Council for Graduate Medical Education (ACGME) say that they ... MPH, of Harvard Medical School, and colleagues said that ...
... the September issue of Archives of Pediatrics & Adolescent Medicine, ... prepared in the event of a conflict// and have trained ... need urgent medical care. The report is based on the ... ,Military hospitals are likely to encounter injured children as wars ...
... of Japan, who gave birth to a male heir today, ... for transplantation to leukemia patients, Masao// Nakabayashi, director of Aiiku ... Princess Kiko made the offer after she gave birth by ... on her request," Nakabayashi told reporters. Experts say that the ...
... leader in oral care, in association with the Indian ... observed as Oral Health Month. Now in its third ... oral health awareness campaign in India to establish and ... all ages. This year, the theme of Oral Health ...
... the pizza melts away in your mouth, you might just ... in this delicious spread.// A novel study has served the ... calorie content of fast-food meals. Although the estimations were accurate ... ,Pierre Chandon, a co-author of the study ...
Cached Medicine News:Health News:Military Hospitals Need To Be Prepared To Treat Children 2Health News:Striving to Make India Free from Tooth Decay 2
Inquire...
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum....
... For over 30 years, Digisonics has ... workstations with the first review station, ... management, and the best multi-modality reporting., ... performance image review workstations, professional reporting ...
... glucocorticoid produced by the adrenal cortex in ... secreted with a circadian periodicity, and peaks ... Cortisol is often elevated in major depressive ... and in the visceral fat of obese ...
Medicine Products: